GS-0976 (Firsocostat): an investigational liver-directed acetyl-CoA carboxylase (ACC) inhibitor for the treatment of non-alcoholic steatohepatitis (NASH)

INTRODUCTION: De novo lipogenesis (DNL) plays a major role in fatty acid metabolism and contributes significantly to triglyceride accumulation within the hepatocytes in patients with nonalcoholic steatohepatitis (NASH). Acetyl-CoA carboxylase (ACC) converts acetyl-CoA to malonyl CoA, and is a rate-c...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Expert Opin Investig Drugs
Asıl Yazarlar: Alkhouri, Naim, Lawitz, Eric, Noureddin, Mazen, DeFronzo, Ralph, Shulman, Gerald I.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2019
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7063378/
https://ncbi.nlm.nih.gov/pubmed/31519114
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/13543784.2020.1668374
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller